PayerTalkCE Presents: Psoriasis Health Plan Best Practices: Overcoming Access Barriers to Advanced Treatments

Learn About:

Approaches to enhance timely, equitable access to evidence-based psoriasis care
How comorbidities, patient history, and preferences influence treatment decisions
The role of newly approved and emerging psoriasis therapies

Expert Faculty Presenters


	Jeffrey D. Dunn, PharmD, MBA President and CEO Cooperative Benefits Group (CBG) Click here for biography

	Adam Friedman, MD, FAAD Professor and Chair of Dermatology Associate Residency Program Director Director of Translational Research Director of Supportive Oncodermatology Department of Dermatology George Washington School of Medicine and Health Sciences Click here for biography

	Susan Wescott, RPh, MBA Senior Director of Pharmacy, Managed Care Mayo Clinic Click here for biography

Target Audience
The primary target audience for this activity consists of managed care pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, medical directors, members of the AMCP, and other managed health care professionals attending the AMCP eLearning Day.

Statement of Need/Program Overview
The psoriasis treatment landscape is rapidly evolving. Although treatment guidelines are routinely updated, ongoing innovation and the introduction of new therapies frequently render even the most current guidelines incomplete. During this AMCP eLearning Day symposium, managed care decision makers will expand their knowledge and learn about the importance of early intervention, prevention, and treatment of associated comorbidities, promotion of healthy lifestyle changes, and implementation of personalized treatment plans.

Educational Objectives
After completing this activity, participants should be able to demonstrate improved ability to:

Analyze the role of newly approved and emerging psoriasis therapies in care planning across different disease severities
Identify how comorbidities, patient history, and preferences influence treatment decisions
Assess approaches to enhance timely, equitable access to evidence-based care for individuals living with psoriasis

Accreditation Information

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and Impact Education, LLC. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Interprofessional Continuing Education (IPCE)
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Physician Continuing Medical Education
Partners designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Partners designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education.

UAN: Coming Soon
Type of Activity: Knowledge

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

DISCLOSURE OF CONFLICTS OF INTEREST
Partners for Advancing Clinical Education (Partners) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to Partners policy. Partners is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

*Name of Faculty*	*Reported Financial Relationship*
Jeff Dunn, PharmD, MBA	Nothing to disclose.
Adam Friedman, MD, FAAD	Coming soon
Susan Wescott, RPh, MBA	Nothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

FEE INFORMATION
There is no fee for this educational activity.